CytoSorbents 2025 revenue rises, net loss narrows

Overview

• U.S. blood purification device maker's 2025 revenue grew 4%, flat on constant currency

• Company implemented workforce and cost reduction program in Q4

• Secured $2.5 mln additional liquidity through amended credit facility in November

Outlook

• CytoSorbents expects to achieve cash flow breakeven in the second half of 2026

• CytoSorbents expects incremental improvement in commercial activity across 2026

Result Drivers

• GERMAN SALES DECLINE - Co said 10% drop in Germany annual sales reflected restructuring of sales operations and new strategies

• COST REDUCTION - Co implemented workforce and cost reduction program in Q4 to lower expenses and accelerate cash flow breakeven

Company press release: ID:nPnc7zYJHa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Cytosorbents Corp is $5.00, about 618.6% above its March 24 closing price of $0.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.